Medivation (MDVN) Target of Negative TheStreetSweeper Article
Tweet
Share
E-mailGet Alerts MDVN Hot Sheet
Join SI Premium – FREE
Medivation, Inc. (Nasdaq: MDVN) is seeing mild pressure Thursday afternoon following a negative report at TheStreetSweeper.org.
The report said, ".... the stock trades at lofty levels that fail to properly reflect the following: rights to only a portion of future drug sales and initial access to only a limited section of the market; fierce competition from a similar drug and documented progress toward a superior version of its own therapy; inexperience in commercial operations and dependence on a marketing partner where sales reps have long complained of toxic working conditions; and prior clinical results that sparked false hopes for an earlier drug that ultimately failed, scaring off an industry giant and staining its record with a potential source of ongoing doubt."
The report said, ".... the stock trades at lofty levels that fail to properly reflect the following: rights to only a portion of future drug sales and initial access to only a limited section of the market; fierce competition from a similar drug and documented progress toward a superior version of its own therapy; inexperience in commercial operations and dependence on a marketing partner where sales reps have long complained of toxic working conditions; and prior clinical results that sparked false hopes for an earlier drug that ultimately failed, scaring off an industry giant and staining its record with a potential source of ongoing doubt."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hunterbrook Capital is short bonds issued by Sammons Financial Group and short Guggenheim Strategic Opportunities Fund
- ​Peltz's Trian has no plan for Wendy's bid currently - Reuters
- Senior Iranian Source To Reuters: An Agreement With Oman Over The Strait Of Hormuz Has Not Yet Been Finalised - Reuters
Create E-mail Alert Related Categories
Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
